Geographic disparity in 10-year mortality after coronary artery revascularization in the SYNTAXES trial

医学 内科学 经皮冠状动脉介入治疗 冠状动脉疾病 传统PCI 心脏病学 血运重建 射血分数 糖尿病 旁路移植 动脉 心肌梗塞 心力衰竭 内分泌学
作者
Shigetaka Kageyama,Patrick W. Serruys,Scot Garg,Kai Ninomiya,Shinichiro Masuda,Nozomi Kotoku,Antonio Colombo,Michael J. Mack,Adrian Banning,Marie‐Claude Morice,Adam Witkowski,Nick Curzen,Francesco Burzotta,Stefan James,Robert‐Jan van Geuns,Piroze Davierwala,David R. Holmes,David Wood,John W. McEvoy,Yoshinobu Onuma
出处
期刊:International Journal of Cardiology [Elsevier BV]
卷期号:368: 28-38 被引量:4
标识
DOI:10.1016/j.ijcard.2022.08.013
摘要

Aims To investigate geographic disparity in long-term mortality following revascularization in patients with complex coronary artery disease (CAD). Methods and results The SYNTAXES trial randomized 1800 patients with three-vessel and/or left main CAD to percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and assessed their survival at 10 years. Patients were stratified according to the region of recruitment: North America (N-A, n = 245), Eastern Europe (E-E, n = 189), Northern Europe (N-E, n = 425), Southern Europe (S-E, n = 263), and Western Europe (W-E, n = 678), which also served as the reference group. Compared to W-E, patients were younger in E-E (62 vs 65 years, p < 0.001), and less frequently male in N-A (65.3% vs 79.6%, p < 0.001). Diabetes (16.0% vs 25.4%, p < 0.001) and peripheral vascular disease (6.8% vs 10.9%, p = 0.025) were less frequent in N-E than W-E. Ejection fraction was highest in W-E (62% vs 56%, p < 0.001). Compared to W-E, the mean anatomic SYNTAX score was higher in S-E (29 vs 31, p = 0.008) and lower in N-A (26, p < 0.001). Crude ten-year mortality was similar in N-A (31.6%), and W-E (30.7%), and significantly lower in E-E (22.5%, p = 0.041), N-E (21.9%, p = 0.003) and S-E (22.0%, p = 0.014). Compared to W-E, adjusted mortality in N-E (HR 0.85, p = 0.019) and S-E (HR 0.72, p = 0.043) remain significantly lower after adjustment for pre- and peri-procedural factors, but no significant interaction (Pinteraction = 0.728) between region and modality of revascularization was seen. Conclusion In the era of globalization, knowledge, and understanding of geographic disparity are of paramount importance for the correct interpretation of global studies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
科研通AI5应助Ezio_sunhao采纳,获得10
4秒前
科研通AI5应助笨笨的复天采纳,获得10
5秒前
5秒前
Annie完成签到 ,获得积分10
5秒前
Akim应助ZYY采纳,获得10
5秒前
共享精神应助zfcc采纳,获得10
6秒前
6秒前
dodo发布了新的文献求助10
7秒前
wzy发布了新的文献求助10
7秒前
洁净之卉发布了新的文献求助50
7秒前
康若英完成签到,获得积分10
7秒前
波波完成签到 ,获得积分10
7秒前
健壮的涑发布了新的文献求助10
7秒前
豆豆完成签到 ,获得积分10
8秒前
万能图书馆应助Qwepo8采纳,获得10
8秒前
9秒前
桐桐应助科研通管家采纳,获得10
9秒前
爆米花应助科研通管家采纳,获得30
9秒前
跳跃的翼应助科研通管家采纳,获得10
9秒前
wanci应助科研通管家采纳,获得10
9秒前
Hello应助科研通管家采纳,获得10
9秒前
Jasper应助科研通管家采纳,获得10
9秒前
思源应助科研通管家采纳,获得10
9秒前
wanci应助科研通管家采纳,获得10
9秒前
科研通AI6应助科研通管家采纳,获得10
9秒前
orixero应助科研通管家采纳,获得10
9秒前
9秒前
科研通AI5应助风屿采纳,获得10
9秒前
MchemG应助科研通管家采纳,获得30
9秒前
华仔应助科研通管家采纳,获得10
9秒前
搜集达人应助科研通管家采纳,获得10
10秒前
领导范儿应助科研通管家采纳,获得10
10秒前
脑洞疼应助科研通管家采纳,获得10
10秒前
chen发布了新的文献求助10
10秒前
烟花应助科研通管家采纳,获得10
10秒前
CodeCraft应助科研通管家采纳,获得10
10秒前
科研通AI5应助科研通管家采纳,获得10
10秒前
传奇3应助科研通管家采纳,获得10
10秒前
英俊的铭应助科研通管家采纳,获得10
10秒前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
LRZ Gitlab附件(3D Matching of TerraSAR-X Derived Ground Control Points to Mobile Mapping Data 附件) 2000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5133034
求助须知:如何正确求助?哪些是违规求助? 4334358
关于积分的说明 13503569
捐赠科研通 4171281
什么是DOI,文献DOI怎么找? 2287061
邀请新用户注册赠送积分活动 1287947
关于科研通互助平台的介绍 1228783